Ivy Leaf (Hedera helix)

Table of Contents

1. What Ivy Is
2. From Folk Remedy to Regulated Medicine
3. The Active Compounds
4. How It Is Thought to Work
5. The Evidence in Adults
6. The Evidence in Children
7. Forms and Doses Used in Studies
8. Safety and Tolerability of the Extract
9. The Living Plant: Rashes and Poisonous Berries
10. Ivy Among the Other Cough Herbs
11. The Honest Bottom Line
12. Key Research Papers
13. Connections
14. Featured Videos

What Ivy Is

Hedera helix belongs to the Araliaceae family, which makes it a botanical relative of ginseng. It is a woody evergreen that grows in two quite different forms on the same plant. The young, climbing stems carry the familiar three- to five-lobed leaves and cling to walls and bark with small aerial rootlets. Once a stem reaches the light and stops climbing, it switches to an "adult" form with unlobed, oval leaves, and only these adult shoots flower. The flowers open in autumn, unusually late in the year, and are followed by clusters of small black berries that ripen through the winter.

The plant is native to Europe and western Asia. It has been planted for ornament on almost every continent and has escaped from gardens in many regions; the North Carolina State Extension plant database, for example, lists it as an invasive species in that state, where it smothers the ground in woodlands and prevents native seedlings from sprouting (NC State Extension: Hedera helix).

The medicinal part is the leaf. The leaves are dried and then extracted with alcohol and water to make a concentrated "dry extract", which is the ingredient in nearly all modern ivy cough medicines. Nobody in the studies described below chewed fresh ivy leaves or brewed a home tea from a garden plant — that distinction runs through this whole page, because the fresh plant brings hazards the standardised extract does not.

A note on names: "ivy" is also part of the common names of several unrelated plants. Poison ivy (Toxicodendron radicans) is not a true ivy at all and causes its rash through a different chemical, urushiol. Ground ivy (Glechoma hederacea) is a member of the mint family. Everything on this page refers only to common or English ivy, Hedera helix.

From Folk Remedy to Regulated Medicine

Ivy leaves have a long history in European folk medicine for coughs and chest complaints, and in older herbals for a range of skin and joint uses. The modern story is about how that folk remedy turned into a regulated medicine.

In Germany, the Commission E — the expert body that reviewed herbal medicines for the German drug regulator from the late 1970s to the 1990s — approved ivy leaf for respiratory use. A 2021 review of ivy in respiratory problems notes this approval and lists the pharmacological activities reported for the plant in laboratory work, including antispasmodic, anti-inflammatory and antimicrobial effects (Baharara 2021).

At the European level, the Committee on Herbal Medicinal Products (HMPC) of the European Medicines Agency publishes an official monograph on ivy leaf. The current version, adopted on 21 November 2017, places specified ivy leaf extracts under well-established use for one indication: an "expectorant in case of productive cough". An expectorant is a medicine intended to loosen mucus so it is easier to cough up. The same monograph contraindicates use in children under two years of age, lists the doses of five defined extract types for adolescents, adults and children aged 2 to 11, and states plainly under pharmacodynamics that "the mechanism of action is not known" (EMA: Hederae helicis folium).

A 2026 review that set out to map the entire evidence chain for ivy leaf — from quality control of the extract to animal pharmacology, absorption, toxicology, clinical trials and regulatory assessment — summarises the regulatory picture the same way: the European Union monograph recognises specified extracts for productive cough, contraindicates use below two years, and does not recommend use during pregnancy or lactation (Pawłowska 2026).

The Active Compounds

The chemistry researchers focus on in ivy leaf is a family of triterpene saponins. Saponins are plant compounds built from a fat-soluble ring skeleton attached to one or more sugar chains; the name comes from their soap-like ability to foam in water.

• Hederacoside C is the most abundant saponin in the dried leaf. It carries sugar chains at two points on the molecule. It is the "marker" compound that the European Pharmacopoeia uses to measure and standardise ivy extracts (Pawłowska 2026).
• Alpha-hederin (α-hederin) carries a sugar chain at one point only, which makes it a "monodesmoside". It can form when hederacoside C loses one of its sugar chains. It is the compound most studied in laboratory models of the beta2-adrenergic receptor (see below).
• Hederagenin is the bare ring skeleton with no sugars attached.
• Hederacosides B and D are further saponins listed among the leaf's constituents (Baharara 2021).

The leaf also contains phenolic compounds and flavonoids common to many plants. And it contains a group of compounds that matter for safety rather than for cough: polyacetylenes, particularly falcarinol, which are the main cause of the skin rashes that gardeners get from handling ivy (see The Living Plant).

It is worth knowing that alpha-hederin is not unique to ivy. Laboratory papers describe it as a compound found in several medicinal plants, including black seed (Nigella sativa) and pasque flower (Pulsatilla). Its extensive anti-cancer literature in cell cultures and mice is a separate research strand from the cough question, and none of that work involves people.

How It Is Thought to Work

Two explanations are commonly given for why ivy leaf might help a chesty cough.

The beta2-receptor explanation

The airways are lined with smooth muscle and with cells that make mucus and fluid. Both carry beta2-adrenergic receptors — the same receptors that asthma reliever inhalers such as salbutamol switch on. When these receptors are activated, airway muscle relaxes and the lining releases more watery secretion, which thins mucus. Receptors that are heavily stimulated tend to be pulled inside the cell ("internalised"), which blunts the response.

In 2009 a laboratory group exposed human cells to the three main ivy saponins. In cells engineered to carry a fluorescent version of the beta2 receptor, a 24-hour pre-treatment with alpha-hederin reduced the receptor's internalisation after stimulation; in human lung-derived cells it increased binding of a receptor-activating molecule; and in human airway smooth-muscle cells it raised the internal messenger cAMP by about 13.5% under stimulating conditions. Hederacoside C and hederagenin did none of these things (Sieben 2009). The 2026 review adds that later cell studies reported changes in the signalling proteins (GRK2 and β-arrestin) that control receptor internalisation (Pawłowska 2026).

This is a coherent laboratory story. It has, however, a gap: the same review reports that rats absorb hederacoside C and alpha-hederin poorly when taken by mouth, and that small exploratory human studies detected no alpha-hederin, or only trace amounts, in the blood (Pawłowska 2026). Whether enough of the compound reaches the airways of a person taking a cough syrup to act on these receptors has not been shown. That is why the EU monograph still says the mechanism is not known. The full story is on the alpha-hederin and beta2 mechanism page.

The classic saponin explanation

An older idea, applied to many saponin-containing cough plants, is that saponins irritate the stomach lining slightly and trigger a reflex through the vagus nerve that increases airway secretions. This "gastric reflex" explanation is widely repeated in herbal texts. It fits with the fact that the most common side effects of ivy extract are gastrointestinal, but it has not been demonstrated directly for ivy in people.

Animal and tissue findings

The 2026 review reports that isolated-tissue and animal studies found antispasmodic (muscle-relaxing), anti-inflammatory, cough-reducing and airway-secretion effects (Pawłowska 2026). These are findings in animals and isolated tissue, not in patients.

The Evidence in Adults

The most useful single source for adults is an independent systematic review from a German general-practice research group, updated in 2021. It searched the medical literature from December 2009 to January 2020 for studies of ivy leaf, alone or in combination, in acute upper respiratory tract infections and bronchitis, and found 6 randomised controlled trials, 1 non-randomised controlled trial and 4 observational studies (Sierocinski 2021).

• Every included study concluded that ivy leaf extract was effective and safe.
• Three of the randomised trials reported a faster reduction in cough severity or frequency with ivy leaf.
• The reviewers judged that the clinical significance of these effects "appears to be minimal".
• No serious adverse effects were reported.
• The overall quality of reporting was low and the risk of bias was high.

Their conclusion: ivy leaf preparations are safe for cough due to acute upper respiratory infections and bronchitis, but "effects are minimal at best and of uncertain clinical importance." The 2026 review takes a somewhat more positive reading of the newer adult trials of one extract, coded EA 575, reporting that placebo-controlled adult trials found greater short-term improvement in cough or in a bronchitis severity score than placebo (Pawłowska 2026).

The largest single dataset is not a trial. A postmarketing study followed 9,657 patients with acute or chronic bronchitis, 5,181 of them children, who took an ivy leaf syrup in routine practice. After seven days, 95% were reported as improved or healed, and 2.1% had an adverse event, mostly gastrointestinal (Fazio 2009). Because there was no comparison group, this study cannot separate the effect of the syrup from the natural course of acute bronchitis, which usually settles on its own within a few weeks. Its value is as a large safety record.

Ivy leaf extract has also served as the established comparator in newer trials. In a 2026 Korean phase 3 trial, 236 patients aged 2 to 70 with acute upper respiratory infection or chronic bronchitis received either a combination of ivy leaf and Coptis rhizome extracts or an ivy leaf extract alone for five days. The two were statistically indistinguishable: cough cleared in 43.0% versus 40.0%, and adverse events occurred in 11.0% versus 11.1% (Cho 2026). The trial shows the two products performed similarly; with no placebo arm, it does not show how either compares with doing nothing.

The detailed trial-by-trial picture is on the cough trials in adults and children page.

The Evidence in Children

Ivy leaf syrups are heavily used for children, and this is where the gap between use and evidence is widest.

A 2003 review re-analysed the original data of trials in children with chronic bronchial asthma. Of five randomised trials of ivy leaf in chronic bronchitis, three were in children and met the criteria; only one of those three compared ivy leaf to placebo. In that one, ivy leaf drops were better than placebo at reducing airway resistance (p = 0.04). The authors concluded that "more far-reaching conclusions can hardly be drawn because of a meagre database" (Hofmann 2003).

A 2014 double-blind, placebo-controlled crossover trial in 30 children aged 6 to 11 with mild persistent allergic asthma, already on inhaled steroid treatment, added four weeks of ivy leaf extract. On the two primary outcomes — the measures the trial was designed to test — no treatment effect was found. Some secondary lung-function measures improved after ivy leaf and not after placebo (Zeil 2014). A null result on the primary outcomes is the main finding of that trial.

A 2023 review of the extract EA 575 in children found 10 controlled trials and 9 observational studies, reported improvements in lung function and cough symptoms in the controlled trials, and a low rate of adverse events in children of all ages, including infants under one year. It still concluded that "more robust clinical trials are needed to confirm its efficacy" (Seifert 2023). A 2025 systematically conducted review of herbal medicines for acute respiratory infections in children found 45 reports, of which only nine were double-blind and placebo-controlled; it judged that only one product, the Pelargonium sidoides root extract EPs 7630, had sufficient evidence, and that for the other herbal products, including ivy leaf, further research is needed (Kamin 2025).

The 2026 review summarises the paediatric picture in one line: paediatric efficacy evidence "is dominated by observational studies and small airway function trials" (Pawłowska 2026).

Forms and Doses Used in Studies

Ivy leaf is almost always taken as a manufactured product made from a dry or liquid extract. Common forms are syrups, drops, effervescent or chewable tablets, and lozenges. Many liquid products contain alcohol, and the EU monograph requires ethanol labelling for them. Combination products pair ivy with thyme, primrose root, marshmallow, licorice or other herbs, and some trials test such combinations rather than ivy alone.

The EU monograph does not give one dose but lists doses for five defined extract types, labelled by their "drug-to-extract ratio" (how many kilograms of dried leaf go into one kilogram of extract) and solvent. For the most common type — a dry extract with a ratio of 4–8:1 made with 24–30% ethanol — the monograph lists, for adolescents, adults and the elderly, a single dose of 15–65 mg one to three times daily, a daily dose of 45–105 mg; for children aged 6 to 11, 33–70 mg a day; and for children aged 2 to 5, 24–36 mg a day, with lower ceilings for products containing ethanol. Doses for the other extract types differ, so a milligram figure from one product cannot be transferred to another.

On duration, the monograph states that if symptoms persist longer than one week during use, a doctor or pharmacist is to be consulted. The trials were short: the Korean comparison ran 5 days, the large postmarketing study 7 days, and the paediatric asthma crossover trial 4 weeks per treatment period (Cho 2026; Fazio 2009; Zeil 2014).

Safety and Tolerability of the Extract

Across the trials and reviews, short-term tolerability of the extract is reported as favourable. The 2026 review names gastrointestinal and hypersensitivity (allergic) reactions as the principal recognised adverse effects (Pawłowska 2026). The specific findings and regulatory statements:

• Children under two. The EU monograph contraindicates use under two years of age "because of the general risk of aggravation of respiratory symptoms through secretolytic drugs" — that is, medicines that loosen mucus can worsen breathing in infants, who cannot clear the extra secretion well. For children aged 2 to 4, the monograph states that persistent or recurrent cough requires a medical diagnosis before treatment. One review of the extract EA 575 reports low adverse-event rates even in infants under one (Seifert 2023); the European regulatory position is nonetheless a contraindication.
• Gastrointestinal reactions. Nausea, vomiting and diarrhoea are listed by the monograph, frequency not known. In the 9,657-patient postmarketing study, gastrointestinal events occurred in 1.5% of patients (Fazio 2009). The monograph notes caution in people with gastritis or stomach ulcer.
• Allergic reactions. Hives, skin rash, breathlessness and anaphylactic reactions are listed, frequency not known. People allergic to ivy or to other plants of the Araliaceae family are contraindicated in the monograph.
• Pregnancy and breastfeeding. Safety has not been established; the monograph does not recommend use for lack of data. No fertility, genotoxicity, carcinogenicity or reproductive toxicity data are available for ivy leaf preparations.
• Overdose. The monograph states that overdose can cause nausea, vomiting, diarrhoea and agitation, and records one 4-year-old who developed aggressiveness and diarrhoea after accidentally swallowing an extract equivalent to 1.8 g of leaf.
• Warning signs. The monograph states that breathlessness, fever or pus-like sputum during use calls for a doctor or pharmacist, because these can signal pneumonia or another illness that a cough medicine does not treat.

More detail is on the safety in children and allergy page.

The Living Plant: Rashes and Poisonous Berries

The extract in a bottle and the plant on the wall are different exposures with different risks.

Skin rashes from handling ivy

Fresh ivy sap causes both irritant and allergic contact dermatitis, typically in people pulling ivy off walls and trees or pruning it. DermNet, the New Zealand dermatology reference, identifies falcarinol and didehydrofalcarinol as the main allergens and describes an itchy, blistering rash on exposed skin — hands, arms, face and neck — that can resemble poison ivy (DermNet: English ivy). Gardeners and landscape workers are the most exposed group. Ivy leaf cough medicines are not known for this reaction, because the rash comes from skin contact with sap.

Breathing ivy at work

A 2008 report in the journal Allergy describes occupational asthma caused by ivy (Hannu 2008), showing that airborne exposure in a work setting can sensitise the airways as well as the skin.

Eating the plant

The berries and leaves are poisonous when eaten. The North Carolina State Extension plant database lists triterpenoid saponins and polyacetylene compounds as the toxic principles and gives the poison severity as medium; it records burning in the throat after eating berries, and vomiting, abdominal pain, fever, rash and, in larger amounts, delirium, stupor, hallucinations and convulsions after eating leaves (NC State Extension: Hedera helix). The saponin doses in a garden plant are not standardised the way an extract is, which is one reason regulators approve specified extracts rather than the leaf itself.

Ivy Among the Other Cough Herbs

Ivy is one of a group of herbs listed for post-viral cough in European practice. A 2021 review of non-drug remedies for post-viral acute cough found "some evidence" for honey, glycerol, marshmallow (Althaea officinalis), sundew, Grindelia, ivy, Pelargonium sidoides, elder, thyme, hyaluronic acid and saline, while stating that further rigorous studies are needed for all of them (Ciprandi 2021). A 2020 benefit–risk assessment of herbs for adults with early, mild flu-like symptoms, written in the context of COVID-19, rated the balance as "positive" for five herbs, ivy among them, alongside marshmallow, licorice, myrrh and elder (Silveira 2020).

Two points stand out in the comparisons. First, among herbal medicines for children's respiratory infections, a 2025 review funded by a herbal-medicine manufacturer judged the strongest evidence to belong to Pelargonium extract EPs 7630, not to ivy (Kamin 2025). Second, thyme and ivy are frequently combined in the same product, so many "ivy" studies are really ivy-plus-something studies. The site's Thyme page covers thyme on its own, and the comparison is set out on the ivy leaf vs thyme and other cough herbs page.

The Honest Bottom Line

Ivy leaf extract is a regulated herbal medicine in the European Union, approved under well-established use as an expectorant for productive cough, with a large record of use and a reassuring short-term tolerability profile in tens of thousands of patients. The clinical evidence is extensive in volume but weak in design: many uncontrolled observational studies, few placebo-controlled trials, a high risk of bias, and effects on cough that an independent review judged "minimal at best". In children, the placebo-controlled evidence is thin, a well-designed asthma crossover trial missed its primary outcomes, and European regulators contraindicate use under two years of age.

The beta2-receptor mechanism is a laboratory finding about one saponin, alpha-hederin, that barely shows up in human blood after oral doses; the EU monograph lists the mechanism as unknown. The fresh plant is a different matter altogether: its sap causes skin rashes and its berries and leaves are poisonous to eat. Most acute coughs from colds settle on their own; a cough with breathlessness, fever or coloured sputum, or a cough that lasts more than a week or two, is a medical question rather than a herbal one, and decisions about any medicine for a young child belong with a clinician.

Key Research Papers

1. Sierocinski E, Holzinger F, Chenot JF. Ivy leaf (Hedera helix) for acute upper respiratory tract infections: an updated systematic review. European journal of clinical pharmacology. 2021;77(8):1113-1122. PubMed PMID: 33523253
2. Pawłowska AM. From Traditional Remedy to Evidence-Based Phytotherapeutic Agent: Hedera helix L. in Respiratory Medicine. Plants (Basel, Switzerland). 2026;15(17). PubMed PMID: 42739377
3. Baharara H, Moghadam AT, Sahebkar A, et al. The Effects of Ivy (Hedera helix) on Respiratory Problems and Cough in Humans: A Review. Advances in experimental medicine and biology. 2021;1328:361-376. PubMed PMID: 34981489
4. Fazio S, Pouso J, Dolinsky D, et al. Tolerance, safety and efficacy of Hedera helix extract in inflammatory bronchial diseases under clinical practice conditions: a prospective, open, multicentre postmarketing study in 9657 patients. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2009;16(1):17-24. PubMed PMID: 16860549
5. Cho YJ, Yoon HJ, Lim DH, et al. Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms. Journal of Korean medical science. 2026;41(9):e97. PubMed PMID: 41807028
6. Hofmann D, Hecker M, Völp A. Efficacy of dry extract of ivy leaves in children with bronchial asthma--a review of randomized controlled trials. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2003;10(2-3):213-20. PubMed PMID: 12725580
7. Zeil S, Schwanebeck U, Vogelberg C. Tolerance and effect of an add-on treatment with a cough medicine containing ivy leaves dry extract on lung function in children with bronchial asthma. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2014;21(10):1216-20. PubMed PMID: 24916707
8. Seifert G, Upstone L, Watling CP, et al. Ivy leaf dry extract EA 575 for the treatment of acute and chronic cough in pediatric patients: review and expert survey. Current medical research and opinion. 2023;39(10):1407-1417. PubMed PMID: 37731370
9. Kamin W, Seifert G, Zwiauer K, et al. Phytotherapy for acute respiratory tract infections in children: a systematically conducted, comprehensive review. Frontiers in pediatrics. 2025;13:1423250. PubMed PMID: 40376625
10. Sieben A, Prenner L, Sorkalla T, et al. Alpha-hederin, but not hederacoside C and hederagenin from Hedera helix, affects the binding behavior, dynamics, and regulation of beta 2-adrenergic receptors. Biochemistry. 2009;48(15):3477-82. PubMed PMID: 19278262
11. Hannu T, Kauppi P, Tuppurainen M, et al. Occupational asthma to ivy (Hedera helix). Allergy. 2008;63(4):482-3. PubMed PMID: 18315739
12. Ciprandi G, Tosca MA. Non-pharmacological remedies for post-viral acute cough. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace. 2021;92(1). PubMed PMID: 34461702
13. Silveira D, Prieto-Garcia JM, Boylan F, et al. COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy? Frontiers in pharmacology. 2020;11:581840. PubMed PMID: 33071794

PubMed Topic Searches

1. PubMed: Hedera helix cough
2. PubMed: ivy leaf extract randomized trials
3. PubMed: alpha-hederin beta2-adrenergic receptor
4. PubMed: Hedera helix contact dermatitis

Back to Table of Contents

Connections

• Respiratory and Lung Herbs — the category this herb belongs to
• Ivy Leaf: Benefits Deep Dive — the evidence ledger and four deep-dive articles
• Cough Trials in Adults and Children — what each study found
• Alpha-Hederin and the Beta2 Mechanism — the laboratory explanation
• Safety in Children and Allergy — the under-two contraindication and allergy reports
• Ivy Leaf vs Thyme and Other Cough Herbs — how the evidence compares
• Thyme — the herb most often combined with ivy
• Marshmallow Root — a mucilage cough herb
• Elecampane — a traditional expectorant
• Mullein — a traditional cough and chest herb
• Ginseng — ivy's best-known relative in the Araliaceae family
• Black Seed — another plant source of alpha-hederin
• Bronchitis — the condition most ivy trials studied
• Chronic Cough — when a cough lasts
• Asthma — the subject of the paediatric lung-function trials
• Common Cold — the usual cause of acute cough
• Contact Dermatitis — the rash fresh ivy sap can cause

Back to Table of Contents

Featured Videos